# Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528

> **NCT01536574** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 295 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Requip PR

## Key facts

- **NCT ID:** NCT01536574
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-02
- **Primary completion:** 2012-03-01
- **Final completion:** 2012-03-28
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01536574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01536574, "Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01536574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*